Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.

Certain skin and family history markers predict vitiligo severity and treatment needs.

Scalp involvement in primary cutaneous lymphomas is common and can be aggressive, requiring careful attention.

RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

Most patients with frontal fibrosing alopecia are postmenopausal women, and treatments like finasteride and dutasteride can improve or stabilize the condition.

Alopecia areata causes varying hair loss patterns, affecting hair, nails, and possibly glands, with treatment outcomes depending on disease duration and extent.

Advanced male pattern baldness affects the back of the scalp, reducing hair follicles.

European patent law now allows patents for new uses and dosages of known drugs, but protection scope is unclear.

TGM3 is important for skin and hair structure and may help diagnose cancer.

Natural killer and CD8+ T cells play a key role in hair loss in androgenetic alopecia.

Early diagnosis using eye tests and lab markers can improve treatment for pediatric Sjögren's syndrome.

Inhibiting certain brain neurons may reduce pain and anxiety in trigeminal neuralgia.

Tight junctions help control skin shedding and may be targets for treating certain skin conditions.

Alopecia Areata affects young adults more in high-income countries, especially females.

17β-estradiol boosts APE1/Ref-1 secretion in cells and mice via a calcium-dependent pathway.

Understanding keratinization is crucial for treating skin conditions like ichthyoses and psoriasis.

MicroRNA-181a slows sheep hair growth by targeting GNAI2 and affecting a key growth pathway.

Adults with alopecia areata often have empty follicular openings, while children show more honeycomb pigment patterns.

5-alpha reductase inhibitors and spironolactone don't increase gynecological tumor risk, glucagon-like-peptide-1 receptor agonists may increase alopecia risk, sanitary pads can cause dermatitis, early hidradenitis suppurativa intervention is crucial for Hispanic patients, community education boosts skin cancer awareness, metformin may improve skin cancer survival, LNG-IUDs can increase acne risk, machine learning accurately detects basal cell carcinoma, JAK-inhibitors may raise miscarriage risk, inclusive skincare ads affect those with darker skin, and CCCA in Black women might involve autoimmunity.

Minoxidil improves hair loss in breast cancer patients on CDK4/6-inhibitor therapy.

Tailored treatments for alopecia areata are recommended based on severity and patient needs.

Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.

Most men with Frontal fibrosing alopecia also lose facial hair and the condition may be linked to hormone levels and sunscreen use.

Children with alopecia areata before age 4 may have better short-term hair regrowth.

Lichen planopilaris should be considered in diagnosing scarring hair loss in Black women.

Body hair transplants can treat baldness but differ from scalp hair and need more research on long-term results and side effects.

Frontal fibrosing alopecia is a poorly understood condition with increasing cases and unclear treatment effectiveness.

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

Ophiasis mainly affects females, lasts longer, and has lower regrowth rates, with a new classification system helping predict treatment response.